Vincristine
Showing 1 - 25 of 1,388
Pediatric Cancer Trial in Eldoret (Vincristine)
Recruiting
- Pediatric Cancer
- Vincristine
-
Eldoret, Rift Valley, KenyaMoi Teaching and Referral Hospital
Apr 25, 2023
Langerhans Cell Histiocytosis Trial in Shanghai (Prednisone+Cytarabine+vincristine,
Recruiting
- Langerhans Cell Histiocytosis
-
Shanghai, ChinaShanghai Children's Medical Center
Jul 23, 2022
Vincristine-induced Peripheral Neuropathy in Adult Survivors of
Not yet recruiting
- Chemotherapy-induced Peripheral Neuropathy
- self-administered questionnaire
- (no location specified)
Feb 24, 2023
Breast Cancer, Chemo Effect Trial in Beijing (Chidamide)
Recruiting
- Breast Cancer
- Chemotherapy Effect
-
Beijing, Beijing, ChinaNational Cancer Center/National Clinical Research Center for Can
Feb 17, 2023
Sarcoma, Ewing, Rhabdomyosarcoma Trial run by the National Cancer Institute (NCI) (PEN-866, Vincristine, Temozolomide)
Not yet recruiting
- Sarcoma, Ewing
- Rhabdomyosarcoma
- PEN-866
- +2 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Aug 24, 2022
Retinoblastoma, Retinal Tumor Trial in Memphis (procedure, drug, radiation, other)
Active, not recruiting
- Retinoblastoma
- Retinal Neoplasm
- Enucleation
- +9 more
-
Memphis, TennesseeSt. Jude Children's Research Hospital
Jan 10, 2022
Optic Glioma, Pediatric Brain Tumor, Optic Nerve Glioma Trial in Beijing (Carboplatin, Vincristine, Recombinant human
Recruiting
- Optic Glioma
- Pediatric Brain Tumor, Optic Nerve Glioma
- Carboplatin
- +2 more
-
Beijing, ChinaCapital Medical University Sanbo Brain Hospital
Jul 4, 2022
iPSC Neurons From Adult Survivors of Childhood Cancer Who Have
Active, not recruiting
- Leukemia
- Lymphoma
-
Memphis, TennesseeSt. Jude Children's Research Hospital
May 16, 2022
Ewing Sarcoma Trial in Beijing (Vincristine, Temozolomide)
Recruiting
- Ewing Sarcoma
- Vincristine
- Temozolomide
-
Beijing, Beijing, ChinaPeking University People's Hospital
Oct 31, 2022
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Blasts 5 Percent or More of Bone Marrow Nucleated Cells,
Terminated
- Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
- +10 more
- Cytarabine
- +3 more
-
Los Angeles, CaliforniaUSC / Norris Comprehensive Cancer Center
Nov 17, 2021
Solid Tumors, Primary Brain Tumors Trial in United States (Vincristine, Irinotecan, Temozolomide)
Completed
- Solid Tumors
- Primary Brain Tumors
- Vincristine
- +3 more
-
Hartford, Connecticut
- +13 more
Jan 12, 2023
Neuroblastoma, Pediatric Cancer Trial in New York (Cyclophosphamide, Topotecan, Vincristine)
Recruiting
- Neuroblastoma
- Pediatric Cancer
- Cyclophosphamide
- +7 more
-
New York, New YorkMemorial Sloan Kettering Cancer Center
Jan 11, 2023
Multiple Myeloma and Plasma Cell Tumor Trial in Buffalo (dexamethasone, doxorubicin HCl, thalidomide)
Completed
- Multiple Myeloma and Plasma Cell Neoplasm
- dexamethasone
- +3 more
-
Buffalo, New YorkRoswell Park Cancer Institute
Sep 30, 2022
Treatment-naïve, Peripheral T Cell Lymphoma Trial in Guangzhou (Dose-finding stage: Liposomal mitoxantrone HCl,
Recruiting
- Treatment-naïve
- Peripheral T Cell Lymphoma
- Dose-finding stage: Liposomal mitoxantrone hydrochloride, Cyclophosphamide, Vincristine and Prednisone
- Dose-expansion stage: Liposomal mitoxantrone hydrochloride, Cyclophosphamide, Vincristine and Prednisone
-
Guangzhou, Guangdong, ChinaSun Yat-sen University Cancer Center
Jul 26, 2021
Allogeneic Hematopoietic Stem Cell Transplantation Recipient, Blasts 5 Percent or More of Bone Marrow Nucleated Cells, Blasts 5
Withdrawn
- Allogeneic Hematopoietic Stem Cell Transplantation Recipient
- +7 more
- Inotuzumab Ozogamicin
- +2 more
-
Buffalo, New YorkRoswell Park Cancer Institute
Jan 13, 2022
Peripheral T-cell Lymphoma Trial in Tianjin (Lposomal mitoxantrone HCl,Cyclophosphamide,Vincristine,Etoposide and
Not yet recruiting
- Peripheral T-cell Lymphoma
- Lposomal mitoxantrone hydrochloride,Cyclophosphamide,Vincristine,Etoposide and Prednisone(CMOEP)
-
Tianjin, Tianjin, ChinaTianjin Medical University Cancer Insititute & Hospital
Jul 13, 2022
Solid Tumor Trial in Dallas (Atezolizumab, Vincristine, Irinotecan)
Not yet recruiting
- Solid Tumor
- Atezolizumab
- +3 more
-
Dallas, TexasThe University of Texas Southwestern Medical Center
Aug 30, 2022
Acute Bilineal Leukemia, Acute Biphenotypic Leukemia, Acute Leukemia of Ambiguous Lineage Trial in Houston (Clofarabine,
Recruiting
- Acute Bilineal Leukemia
- +7 more
- Clofarabine
- +8 more
-
Houston, TexasM D Anderson Cancer Center
Aug 18, 2022
Primary CNS Lymphoma Trial in Moscow (Rituximab, Methotrexate, Vincristine, Procarbazine, Lenalidomide)
Recruiting
- Primary CNS Lymphoma
- Rituximab, Methotrexate, Vincristine, Procarbazine, Lenalidomide
-
Moscow, Russian FederationNathional Medical Research Center for Hematology
Jun 16, 2022
Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma Trial in Seattle (drug, other, biological)
Completed
- Acute Lymphoblastic Leukemia
- Lymphoblastic Lymphoma
- Cyclophosphamide
- +8 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Jun 18, 2022
DLBCL Trial in Cleveland (Loncastuximab tesirine, Prednisone, Rituximab)
Withdrawn
- Diffuse Large B-Cell Lymphoma
- Loncastuximab tesirine
- +5 more
-
Cleveland, OhioUniversity Hospitals Cleveland Medical Center
Mar 15, 2022
Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Follicular Lymphoma Grade IIIb Trial in Guangzhou (Toripalimab,
Recruiting
- Diffuse Large B Cell Lymphoma
- +5 more
- Toripalimab, Rituximab
- R-CHOP Protocol
-
Guangzhou, Guangdong, ChinaDepartment of hematology department, Nanfang hospital
Apr 6, 2022
Diffuse Large B Cell Lymphoma Trial (Rituximab, Cyclophosphamide, Doxorubicin)
Not yet recruiting
- Diffuse Large B Cell Lymphoma
- Rituximab
- +7 more
- (no location specified)
Apr 24, 2022